Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

2.83
0.0000
Post-market: 2.80-0.0300-1.06%19:30 EDT
Volume:911.40K
Turnover:2.54M
Market Cap:280.59M
PE:-3.19
High:2.86
Open:2.86
Low:2.75
Close:2.83
52wk High:4.83
52wk Low:2.75
Shares:99.15M
Float Shares:62.35M
Volume Ratio:0.68
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8867
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:1.80
PE(LYR):-1.51

Loading ...

X4 Pharmaceuticals Issues Options for 80,000 Shares Under 2019 Inducement Plan for New Hires

Reuters
·
Yesterday

Press Release: X4 Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Yesterday

X4 Pharmaceuticals Down over 13%, on Track for Largest Percent Decrease Since June 2025

Dow Jones
·
Sep 09

X4 Pharmaceuticals Says FDA Backs Reduced Enrollment Target for 4WARD Phase 3 Chronic Neutropenia Trial

Reuters
·
Sep 08

X4 Pharmaceuticals - FDA Indicates Proposed Safety Database Acceptable for Potential Snda

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - FDA Agrees to Reduced Sample Size for 4Ward Phase 3 Trial

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - 4Ward Trial Enrollment Expected to Complete by Year-End 2026; Topline Data in H1 2028

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

X4 Pharmaceuticals Grants New Hires Options for 50,000 Shares at $4.04 Each

Reuters
·
Sep 02

X4 Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate

Benzinga Earnings
·
Aug 07

X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million

Reuters
·
Aug 07

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 07

X4 Pharmaceuticals Inc Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05

X4 Pharmaceuticals Issues Inducement Stock Options for 12,000 Shares at $3.98 Each

Reuters
·
Aug 04

X4 Pharmaceuticals Inc : Wells Fargo Initiates Coverage with Overweight Rating; Price Target $11

THOMSON REUTERS
·
Jul 10

X4 Pharmaceuticals Issues Inducement Stock Options for 750,000 Shares at $4.03 Each

Reuters
·
Jul 08

X4 Pharmaceuticals Director Kelly Gold Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Press Release: X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to Its Board of Directors

Dow Jones
·
Jul 01